Michelle Robertson Sells 1,744 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) Stock

Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson sold 1,744 shares of the stock in a transaction on Tuesday, January 11th. The stock was sold at an average price of $25.70, for a total value of $44,820.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ EDIT opened at $22.10 on Friday. Editas Medicine, Inc. has a 1 year low of $20.90 and a 1 year high of $83.95. The business’s 50-day moving average is $30.51 and its 200 day moving average is $43.37.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Monday, November 8th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.24. The company had revenue of $6.20 million for the quarter, compared to analysts’ expectations of $4.92 million. Editas Medicine had a negative return on equity of 38.28% and a negative net margin of 871.91%. Editas Medicine’s quarterly revenue was down 90.1% on a year-over-year basis. During the same period last year, the firm earned $0.12 earnings per share. As a group, analysts anticipate that Editas Medicine, Inc. will post -3.16 EPS for the current fiscal year.

A number of brokerages recently issued reports on EDIT. Stifel Nicolaus lowered their price objective on Editas Medicine from $65.00 to $46.00 and set a “hold” rating on the stock in a research report on Thursday, September 30th. Chardan Capital restated a “buy” rating and set a $75.00 price target on shares of Editas Medicine in a research report on Thursday, September 30th. SVB Leerink began coverage on Editas Medicine in a research report on Tuesday, October 19th. They set a “market perform” rating and a $41.00 price target on the stock. Morgan Stanley lowered their price target on Editas Medicine from $37.00 to $24.00 and set an “underweight” rating on the stock in a research report on Thursday, January 6th. Finally, Robert W. Baird restated a “buy” rating on shares of Editas Medicine in a research report on Wednesday, October 20th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Editas Medicine currently has an average rating of “Hold” and a consensus target price of $54.29.

Several hedge funds and other institutional investors have recently bought and sold shares of EDIT. Envestnet Asset Management Inc. grew its stake in shares of Editas Medicine by 15.7% in the second quarter. Envestnet Asset Management Inc. now owns 31,684 shares of the company’s stock worth $1,795,000 after purchasing an additional 4,295 shares during the last quarter. Rockefeller Capital Management L.P. boosted its position in Editas Medicine by 22.7% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 2,514 shares of the company’s stock valued at $142,000 after acquiring an additional 465 shares in the last quarter. Citigroup Inc. boosted its position in Editas Medicine by 30.5% during the 2nd quarter. Citigroup Inc. now owns 143,366 shares of the company’s stock valued at $8,121,000 after acquiring an additional 33,485 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in Editas Medicine by 21.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 29,796 shares of the company’s stock valued at $1,688,000 after acquiring an additional 5,361 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ boosted its position in Editas Medicine by 3.0% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 41,134 shares of the company’s stock valued at $2,330,000 after acquiring an additional 1,182 shares in the last quarter. 75.93% of the stock is currently owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.

Recommended Story: Beige Book

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.